论文部分内容阅读
目的探讨胰激肽原酶联合肾康注射液治疗糖尿病肾病的疗效。方法选取西华县人民医院2015年1—6月收治的糖尿病肾病患者80例,按照随机数字表法分为对照组和观察组,各40例。对照组患者在常规治疗基础上联合胰激肽原酶治疗,观察组患者在对照组基础上联合肾康注射液治疗,14d为1个疗程。比较两组患者治疗前后24h尿蛋白排泄量及不良反应发生情况。结果治疗前,两组患者24h尿蛋白排泄量比较,差异无统计学意义(P>0.05);治疗后,观察组患者24h尿蛋白排泄量少于对照组,差异有统计学意义(P<0.05)。观察组无不良反应发生。结论胰激肽原酶联合肾康注射液治疗糖尿病肾病疗效显著,无明显不良反应,值得在临床上推广应用。
Objective To investigate the efficacy of pancreatic kallikrein combined with Shenkang injection in the treatment of diabetic nephropathy. Methods Eighty patients with diabetic nephropathy who were treated in Xihua County People’s Hospital from January to June in 2015 were divided into control group and observation group according to random number table. The patients in the control group were treated with pancreatic kallikrein on the basis of routine treatment. The patients in the observation group were treated with Shenkang Injection on the basis of the control group, and 14 days were treated by one course of treatment. 24h urinary protein excretion and adverse reactions before and after treatment were compared between two groups. Results Before treatment, 24h urinary protein excretion was no significant difference between the two groups (P> 0.05). After treatment, the excretion of urinary protein in 24 hours in the observation group was less than that in the control group, the difference was statistically significant (P <0.05 ). Observation group no adverse reactions occurred. Conclusions Pancreatic kallikrein combined with Shenkang injection in the treatment of diabetic nephropathy has obvious curative effect and no obvious adverse reactions, so it is worth popularizing and applying in clinic.